Julia Margaretha Elizabeth Berends

Ms. Julia Margaretha Elizabeth Berends

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JBJulia Margaretha Elizabeth Berends
Julia Margaretha Elizabeth Berends
JWJonna Wimmenhove
Jonna Wimmenhove
MHMarcel Hoppentocht
Marcel Hoppentocht
PHPaul Hagedoorn
Paul Hagedoorn
HFHenderik Frijlink
Henderik Frijlink
FGFloris Grasmeijer
Floris Grasmeijer
Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These two products differ substantially in terms of inhaler design, their use and resistance, and their powder formulations. This study aimed to investigate whether these differences translate into in vitro differences in aerosol characteristics and dissolution kinetics and whether any differences were also reflected in the in vivo performance. Methods: The in vitro aerosol characteristics were determined via Next Generation Impactor experiments, and the dissolution kinetics were determined with a modified paddle apparatus. A randomized crossover comparative bioavailability study with fasted healthy volunteers was conducted with Inbrija 84 mg and Levodopa Cyclops 45 mg, 90 mg, and 135 mg. Results: The results showed similar aerosol characteristics, but Levodopa Cyclops showed substantially faster dissolution behavior than Inbrija. Despite this in vitro difference, the pharmacokinetic profiles of Inbrija 84 mg and Levodopa Cyclops 90 mg were similar, with no differences in Cmax, Tmax, and AUC, showing bioequivalence between the two products. Conclusions: This suggests that the systemic absorption of levodopa via the lungs is not limited by dissolution but most likely by its permeation rate. This finding underscores the need to critically apply in vitro tests and critically interpret the results for predicting the in vivo performance of inhaled products.

3 August 2026 in European Journal of Endocrinology
Verified
Journal Article
Open access
JBJulia Margaretha Elizabeth Berends
Julia Margaretha Elizabeth Berends
AVAnnet Vulto
Annet Vulto
PWPascalle A van Den Wijngaard
Pascalle A van Den Wijngaard
MVMichel Vos
Michel Vos
DTDaan J Touw
Daan J Touw
ABAndré P. van Beek
André P. van Beek
Objective: An adrenal crisis is a potentially life-threatening medical emergency that requires rapid treatment with glucocorticoids. Guidelines advise immediate self-administration of hydrocortisone by intramuscular injection using an emergency management kit in case an adrenal crisis is suspected. However, self-injection is often not performed due to administration complexity or patient anxiety. Pulmonary administration of glucocorticoids may be a more patient-friendly and suitable alternative, especially when administered using a dry powder inhaler. Before advancing to the development of a dry powder inhaler, we aimed to evaluate whether the pharmacokinetics of inhaled prednisolone sodium succinate are suitable for the outpatient treatment of adrenal crisis. Methods: Twelve healthy participants (aged 23-31 years, 50% females) received 2 separate doses of prednisolone sodium succinate, equivalent to 56.1 and 112.2 mg prednisolone on separate occasions, administered via a nebulizer. The primary outcome was the time to reach a target plasma concentration of 200 nmol/L. Results: The median times to achieve this plasma concentration (excluding the nebulization time of approximately 10 minutes) were 17 (13-23) minutes and 9 (5-11) minutes for the 56.1 and 112.2 mg doses, respectively. Furthermore, pulmonary-administered prednisolone sodium succinate was well tolerated. Conclusion: The results of this study, particularly the short time to the target plasma concentration, indicate that prednisolone sodium succinate is rapidly absorbed via the lungs and that the pharmacokinetics of inhaled nebulized prednisolone sodium succinate are suitable for the outpatient treatment of adrenal crisis.